Abstract Title

Saving Life and Limb: Increasing Solubility and Stability of Fully Human Monoclonal Antibodies to Treat Flesh-Eating Infections

Additional Funding Sources

The project described was supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under Grant No. P20GM103408.

Abstract

Group A Streptococcus pyogenes (GAS) is a multi-pathogenic bacteria that posses a broad scope of infection severity. In the most extreme infections, the affected limb must be amputated, and GAS still retains a mortality rate of 24-34%. Fully human monoclonal antibodies (MAb) that are specific to a GAS virulence factor, streptolysin O (SLO), provide hope for a novel therapeutic in combating such traumas, if they can be used in high concentrations. By changing conditions of the vehicle (such as pH and excipients), we demonstrate the solubility of MAbs can be increased without altering antibody structure.

Comments

Sarah Hobdey is also affiliated with the Boise VA Medical Center.

This document is currently not available here.

Share

COinS
 

Saving Life and Limb: Increasing Solubility and Stability of Fully Human Monoclonal Antibodies to Treat Flesh-Eating Infections

Group A Streptococcus pyogenes (GAS) is a multi-pathogenic bacteria that posses a broad scope of infection severity. In the most extreme infections, the affected limb must be amputated, and GAS still retains a mortality rate of 24-34%. Fully human monoclonal antibodies (MAb) that are specific to a GAS virulence factor, streptolysin O (SLO), provide hope for a novel therapeutic in combating such traumas, if they can be used in high concentrations. By changing conditions of the vehicle (such as pH and excipients), we demonstrate the solubility of MAbs can be increased without altering antibody structure.